Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3
Gespeichert in:
| Veröffentlicht in: | Journal for immunotherapy of cancer 2015-11, Vol.3 (Suppl 2), p.O8-O8 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | O8 |
|---|---|
| container_issue | Suppl 2 |
| container_start_page | O8 |
| container_title | Journal for immunotherapy of cancer |
| container_volume | 3 |
| creator | Powderly, John Cote, Gregory Flaherty, Keith Szmulewitz, Russell Z Ribas, Antoni Weber, Jeffrey Loo, Deryk Baughman, Jan Chen, Francine Moore, Paul Bonvini, Ezio Vasselli, James Wigginton, Jon Cohen, Roger Burris, Howard Chmielowski, Bartosz |
| description | |
| doi_str_mv | 10.1186/2051-1426-3-S2-O8 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4645418</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A458157052</galeid><sourcerecordid>A458157052</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4328-d7648d51cf92113131958ca92e7ca9237c4140b51a6a395eee7a110ec1bc98c03</originalsourceid><addsrcrecordid>eNptUl1rFDEUHUTBUvsDfAsIomBq7mQ-Mi_CWmy7UFmh-hyymTs7KTPJmMy0rr_XH2Jmt9RdkAu5yc05JyfJTZLXwM4BRPExZTlQyNKCcnqb0pV4lpw81Z4fzF8mZyHcMcaAcS6EOEn-LO2I3vTEY5i6MRDXEGWJsxtn7IZ8a1VAsvxAahczBq06NRpnSRinejuDv14t0hLIu0tN3TCa3vzGmrRTr-xupuxo6OeSXnPSO-t056zqdtW1q7fvibFkiIpo49EPZmyjj8YrPTq_JTsaxV9D9BZmNxbd0KnQR5f-YPHQzubuVdBTdDf5aHTPwbDXeJW8aFQX8OwxnyY_Lr98v7imN6ur5cXihuqMp4LWZZGJOgfdVCkAj1HlQqsqxXIeeakzyNg6B1UoXuWIWCoAhhrWuhKa8dPk0153mNY91jreyqtODvF9ld9Kp4w83rGmlRt3L7MiyzMQUeDNo4B3PycMo7xzk48vFmRacAEAecH-oTaqQ2ls46KY7k3QcpHlAvKS5WlEnf8HFaPG3mhnsTGxfkR4e0BoUXVjG1w3zf8djoGwB2rvQogf9nRDYHJuSDk3nJwbTnJ5m8qV4H8B2G_UsQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2638111560</pqid></control><display><type>article</type><title>Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3</title><source>BMJ Open Access Journals</source><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Powderly, John ; Cote, Gregory ; Flaherty, Keith ; Szmulewitz, Russell Z ; Ribas, Antoni ; Weber, Jeffrey ; Loo, Deryk ; Baughman, Jan ; Chen, Francine ; Moore, Paul ; Bonvini, Ezio ; Vasselli, James ; Wigginton, Jon ; Cohen, Roger ; Burris, Howard ; Chmielowski, Bartosz</creator><creatorcontrib>Powderly, John ; Cote, Gregory ; Flaherty, Keith ; Szmulewitz, Russell Z ; Ribas, Antoni ; Weber, Jeffrey ; Loo, Deryk ; Baughman, Jan ; Chen, Francine ; Moore, Paul ; Bonvini, Ezio ; Vasselli, James ; Wigginton, Jon ; Cohen, Roger ; Burris, Howard ; Chmielowski, Bartosz</creatorcontrib><identifier>ISSN: 2051-1426</identifier><identifier>EISSN: 2051-1426</identifier><identifier>DOI: 10.1186/2051-1426-3-S2-O8</identifier><language>eng</language><publisher>London: BioMed Central Ltd</publisher><subject>Cancer ; Care and treatment ; Dose-response relationship (Biochemistry) ; Drug dosages ; Immunotherapy ; Kidney cancer ; Melanoma ; Methods ; Oral Presentation ; Patient outcomes ; Patients ; Tumors</subject><ispartof>Journal for immunotherapy of cancer, 2015-11, Vol.3 (Suppl 2), p.O8-O8</ispartof><rights>COPYRIGHT 2015 BioMed Central Ltd.</rights><rights>2015 Powderly et al. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2015 Powderly et al. 2015 Powderly et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4328-d7648d51cf92113131958ca92e7ca9237c4140b51a6a395eee7a110ec1bc98c03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645418/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645418/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Powderly, John</creatorcontrib><creatorcontrib>Cote, Gregory</creatorcontrib><creatorcontrib>Flaherty, Keith</creatorcontrib><creatorcontrib>Szmulewitz, Russell Z</creatorcontrib><creatorcontrib>Ribas, Antoni</creatorcontrib><creatorcontrib>Weber, Jeffrey</creatorcontrib><creatorcontrib>Loo, Deryk</creatorcontrib><creatorcontrib>Baughman, Jan</creatorcontrib><creatorcontrib>Chen, Francine</creatorcontrib><creatorcontrib>Moore, Paul</creatorcontrib><creatorcontrib>Bonvini, Ezio</creatorcontrib><creatorcontrib>Vasselli, James</creatorcontrib><creatorcontrib>Wigginton, Jon</creatorcontrib><creatorcontrib>Cohen, Roger</creatorcontrib><creatorcontrib>Burris, Howard</creatorcontrib><creatorcontrib>Chmielowski, Bartosz</creatorcontrib><title>Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3</title><title>Journal for immunotherapy of cancer</title><subject>Cancer</subject><subject>Care and treatment</subject><subject>Dose-response relationship (Biochemistry)</subject><subject>Drug dosages</subject><subject>Immunotherapy</subject><subject>Kidney cancer</subject><subject>Melanoma</subject><subject>Methods</subject><subject>Oral Presentation</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Tumors</subject><issn>2051-1426</issn><issn>2051-1426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptUl1rFDEUHUTBUvsDfAsIomBq7mQ-Mi_CWmy7UFmh-hyymTs7KTPJmMy0rr_XH2Jmt9RdkAu5yc05JyfJTZLXwM4BRPExZTlQyNKCcnqb0pV4lpw81Z4fzF8mZyHcMcaAcS6EOEn-LO2I3vTEY5i6MRDXEGWJsxtn7IZ8a1VAsvxAahczBq06NRpnSRinejuDv14t0hLIu0tN3TCa3vzGmrRTr-xupuxo6OeSXnPSO-t056zqdtW1q7fvibFkiIpo49EPZmyjj8YrPTq_JTsaxV9D9BZmNxbd0KnQR5f-YPHQzubuVdBTdDf5aHTPwbDXeJW8aFQX8OwxnyY_Lr98v7imN6ur5cXihuqMp4LWZZGJOgfdVCkAj1HlQqsqxXIeeakzyNg6B1UoXuWIWCoAhhrWuhKa8dPk0153mNY91jreyqtODvF9ld9Kp4w83rGmlRt3L7MiyzMQUeDNo4B3PycMo7xzk48vFmRacAEAecH-oTaqQ2ls46KY7k3QcpHlAvKS5WlEnf8HFaPG3mhnsTGxfkR4e0BoUXVjG1w3zf8djoGwB2rvQogf9nRDYHJuSDk3nJwbTnJ5m8qV4H8B2G_UsQ</recordid><startdate>20151104</startdate><enddate>20151104</enddate><creator>Powderly, John</creator><creator>Cote, Gregory</creator><creator>Flaherty, Keith</creator><creator>Szmulewitz, Russell Z</creator><creator>Ribas, Antoni</creator><creator>Weber, Jeffrey</creator><creator>Loo, Deryk</creator><creator>Baughman, Jan</creator><creator>Chen, Francine</creator><creator>Moore, Paul</creator><creator>Bonvini, Ezio</creator><creator>Vasselli, James</creator><creator>Wigginton, Jon</creator><creator>Cohen, Roger</creator><creator>Burris, Howard</creator><creator>Chmielowski, Bartosz</creator><general>BioMed Central Ltd</general><general>BMJ Publishing Group LTD</general><general>BioMed Central</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20151104</creationdate><title>Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3</title><author>Powderly, John ; Cote, Gregory ; Flaherty, Keith ; Szmulewitz, Russell Z ; Ribas, Antoni ; Weber, Jeffrey ; Loo, Deryk ; Baughman, Jan ; Chen, Francine ; Moore, Paul ; Bonvini, Ezio ; Vasselli, James ; Wigginton, Jon ; Cohen, Roger ; Burris, Howard ; Chmielowski, Bartosz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4328-d7648d51cf92113131958ca92e7ca9237c4140b51a6a395eee7a110ec1bc98c03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Cancer</topic><topic>Care and treatment</topic><topic>Dose-response relationship (Biochemistry)</topic><topic>Drug dosages</topic><topic>Immunotherapy</topic><topic>Kidney cancer</topic><topic>Melanoma</topic><topic>Methods</topic><topic>Oral Presentation</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Powderly, John</creatorcontrib><creatorcontrib>Cote, Gregory</creatorcontrib><creatorcontrib>Flaherty, Keith</creatorcontrib><creatorcontrib>Szmulewitz, Russell Z</creatorcontrib><creatorcontrib>Ribas, Antoni</creatorcontrib><creatorcontrib>Weber, Jeffrey</creatorcontrib><creatorcontrib>Loo, Deryk</creatorcontrib><creatorcontrib>Baughman, Jan</creatorcontrib><creatorcontrib>Chen, Francine</creatorcontrib><creatorcontrib>Moore, Paul</creatorcontrib><creatorcontrib>Bonvini, Ezio</creatorcontrib><creatorcontrib>Vasselli, James</creatorcontrib><creatorcontrib>Wigginton, Jon</creatorcontrib><creatorcontrib>Cohen, Roger</creatorcontrib><creatorcontrib>Burris, Howard</creatorcontrib><creatorcontrib>Chmielowski, Bartosz</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal for immunotherapy of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Powderly, John</au><au>Cote, Gregory</au><au>Flaherty, Keith</au><au>Szmulewitz, Russell Z</au><au>Ribas, Antoni</au><au>Weber, Jeffrey</au><au>Loo, Deryk</au><au>Baughman, Jan</au><au>Chen, Francine</au><au>Moore, Paul</au><au>Bonvini, Ezio</au><au>Vasselli, James</au><au>Wigginton, Jon</au><au>Cohen, Roger</au><au>Burris, Howard</au><au>Chmielowski, Bartosz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3</atitle><jtitle>Journal for immunotherapy of cancer</jtitle><date>2015-11-04</date><risdate>2015</risdate><volume>3</volume><issue>Suppl 2</issue><spage>O8</spage><epage>O8</epage><pages>O8-O8</pages><issn>2051-1426</issn><eissn>2051-1426</eissn><cop>London</cop><pub>BioMed Central Ltd</pub><doi>10.1186/2051-1426-3-S2-O8</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2051-1426 |
| ispartof | Journal for immunotherapy of cancer, 2015-11, Vol.3 (Suppl 2), p.O8-O8 |
| issn | 2051-1426 2051-1426 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4645418 |
| source | BMJ Open Access Journals; DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Cancer Care and treatment Dose-response relationship (Biochemistry) Drug dosages Immunotherapy Kidney cancer Melanoma Methods Oral Presentation Patient outcomes Patients Tumors |
| title | Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T02%3A55%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interim%20results%20of%20an%20ongoing%20Phase%20I,%20dose%20escalation%20study%20of%20MGA271%20(Fc-optimized%20humanized%20anti-B7-H3%20monoclonal%20antibody)%20in%20patients%20with%20refractory%20B7-H3-expressing%20neoplasms%20or%20neoplasms%20whose%20vasculature%20expresses%20B7-H3&rft.jtitle=Journal%20for%20immunotherapy%20of%20cancer&rft.au=Powderly,%20John&rft.date=2015-11-04&rft.volume=3&rft.issue=Suppl%202&rft.spage=O8&rft.epage=O8&rft.pages=O8-O8&rft.issn=2051-1426&rft.eissn=2051-1426&rft_id=info:doi/10.1186/2051-1426-3-S2-O8&rft_dat=%3Cgale_pubme%3EA458157052%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2638111560&rft_id=info:pmid/&rft_galeid=A458157052&rfr_iscdi=true |